A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Trial Profile

A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Benegrastim (Primary)
  • Indications Neutropenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Generon (Shanghai) Corporation
  • Most Recent Events

    • 10 Oct 2017 Status changed from recruiting to active, no longer recruiting, according to a Generon Corporation media release.
    • 22 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top